A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

NCT06385678 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced KRAS G12D Mutant Solid Tumors

Interventions

DRUG: HRS-4642
DRUG: Adebrelimab
DRUG: SHR-9839
DRUG: Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection
DRUG: Cetuximab Solution for Infusion

Sponsor

Jiangsu HengRui Medicine Co., Ltd.